Uptitration of Sacubitril/Valsartan in Acute Heart Failure: Insight from the PREMIER Study
Uptitration of Sac/Val therapy yielded a greater NT-proBNP level reduction in AHF patients, but Sac/Val therapy without uptitration also reduced NT-proBNP levels in a subgroup with reduced ejection fraction compared with ACEI/ARB therapy.
Authors
- Shunichi Doi (ORCID: https://orcid.org/0000-0002-9224-4138)
- Keisuke Kida (ORCID: https://orcid.org/0000-0002-3464-6016)
- Atsushi Tanaka (ORCID: https://orcid.org/0000-0003-3352-7661)
- Yuya Matsue (ORCID: https://orcid.org/0000-0003-2456-8525)
- Yukiko Nakano (ORCID: https://orcid.org/0000-0003-1658-8219)
- Yusuke Ueda (ORCID: https://orcid.org/0000-0001-6442-3748)
- Yoshihiro J. Akashi (ORCID: https://orcid.org/0000-0001-7670-7326)
- Takumi Imai (ORCID: https://orcid.org/0000-0002-0541-3467)
- Daiju Fukuda
- Yoshihisa Kizaki
- Koichi Node
Institutions
- Hiroshima University (JP)
- St. Marianna University School of Medicine (JP)
- Saga University (JP)
- Juntendo University (JP)
- Kobe University Hospital (JP)
- Sasebo City General Hospital (JP)
- Osaka Metropolitan University (JP)
- Tokyo Metropolitan University (JP)
Publication Details
- Journal
- Journal of Cardiac Failure
- Published
- 2025-05-17
- DOI
- https://doi.org/10.1016/j.cardfail.2025.05.001
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis Pharmaceuticals Corporation